EATONTOWN, N.J., July 29 /PRNewswire-FirstCall/ — Osteotech, Inc.(Nasdaq: OSTE), a leader in the emerging field of biologic products forregenerative healing, today reported financial results for the secondquarter and six months ended June 30, 2009.
“During the second quarter, we successfully completed several stepsthat have further cleared the pathway toward the achievement of our 2009and 2010 goals,” said Sam Owusu-Akyaw, President and Chief ExecutiveOfficer of Osteotech. “On the clinical development side of our business, wecompleted the enrollment for our DuraTech(TM) BioRegeneration Matrixclinical trial, positioning us well for both regulatory clearance and acommercial launch by the end of 2009. In addition, we also completed twosix month studies utilizing MagniFuse(TM) Bone Graft in advanced animalmodels, results of which we hope to present at various medical meetings in2010. We also plan to use this data as well as a specialized fieldmarketing team to support our third quarter product unveiling as well asour full commercial launch for MagniFuse at the North American SpineSociety meeting in November 2009. On the commercialization side of thebusiness, we completed the limited launch of our Plexur M(TM) Biocompositeand are well prepared for the August launch of our FacetLinx(TM) FusionTechnology for use in facet fusion procedures. In support of our overallcommercialization strategy, we have continued to roll out training andeducation programs focused on highlighting the superior characteristics ofour broad technology platforms and product portfolios. From a trajectoryperspective, we are looking forward to the release of our new productpipeline in the second half in 2009.”